血栓止血バイオマーカー市場規模、シェア、動向分析レポート：製品別、検査場所別、検査タイプ別、用途別、最終用途別、地域別、セグメント予測、2023年～2030年

血栓止血バイオマーカー市場の成長と動向

世界の血栓止血バイオマーカー市場規模は、2023年から2030年にかけてCAGR 5.90％で拡大し、2030年には79億2,000万米ドルに達すると予測されています。

市場の急成長は、膵臓がんなどの慢性疾患の有病率の増加、高齢者人口の増加、個別化医薬品の需要の増加、技術の進歩などの要因に起因しています。

血栓止血バイオマーカー産業は、採用パターンの変化や新規技術のイントロダクションより、近年大きく成長しています。市場におけるPOC分析装置の採用動向の高まりは、小型分析装置の牽引力となっています。小型・超小型機器に関する調査の増加は今後も続くと予想されます。例えば、2022年6月にArnold Lining Ju博士が血栓を検出できるマイクロデバイスの開発を発表し、心臓発作の早期兆候を検出するために使用できるようになっています。

深部静脈血栓症（DVT）、肺塞栓症（PE）、膵臓がんなどの慢性疾患の流行は、止血の可能性を検出する血栓止血バイオマーカーの必要性を高めると予想されます。慢性疾患は血管を損傷する傾向があり、血栓の形成につながって血流を阻害し、脳卒中や心臓発作などの深刻な健康合併症を引き起こす可能性があります。例えば、肺塞栓症（PE）は、脚で発生し、肺に移動して血流を阻害する深刻な病状です。

米国肺協会によると、2023年1月、米国では90万人近くが肺塞栓症に罹患し、肺塞栓症に罹患した人の約33％が10年以内に肺塞栓症を再発すると報告されています。したがって、有病率の高さと症例の大幅な繰り返しが、血栓止血バイオマーカーの需要の増加につながります。

さらに、市場で事業を展開する主要企業は、血栓止血バイオマーカー業界におけるそれぞれの地位を高めるために、合併や買収などさまざまな形の戦略的イニシアチブに注力しています。例えば、2023年1月、サーモフィッシャーサイエンティフィック社は、アストラゼネカ社と提携し、タグリッソの血液ベースおよび固形組織コンパニオン診断テストを製造することを発表しました。これは血栓止血バイオマーカー業界を牽引するものと期待されます。さらに2022年5月、Quidel CorporationはOrtho Clinical Diagnosticsを60億米ドルで買収しました。新会社はQuidelOrthoと命名されました。この買収により、QuidelはOrtho Clinical Diagnosticsのバイオマーカー検査ポートフォリオを利用できるようになっています。

血栓止血バイオマーカー市場レポートハイライト

• 試薬・消耗品市場は2022年に最大の売上シェアを占めたが、これは世界人口における出血および凝固障害の有病率の高まりに起因しています。
• 臨床検査薬は、大量の検体を処理しながら血液凝固過程の異常を診断・同定できることから、2022年の市場全体を牽引した
• ポストトロンビン（PT）検査は、抗凝固薬の有効性をモニタリングできる検査品質に起因し、2022年に最大の売上シェアを占めました。
• 深部静脈血栓症（DVT）は、その高い有病率と高い死亡リスクにより、2022年に最大の売上シェアを占めました。
• 診断センターが2022年に最大の売上シェアを占めたが、これは病院が検査において診断センターへの依存度を高めていることと、より迅速な検査結果を提供するための専門機器の存在別ものです。
• 北米が2022年に市場を席巻したが、これは血栓止血障害の有病率の高さと先端技術へのアクセスに起因しています。
• 主な市場参入企業は、bioMerieux SA、Abbott、Werfen、HORIBA Ltd.、Quidel Corporation、F. Hoffmann-La Roche Ltd.、Diazyme Laboratories, Inc.、Biomedica Diagnostics、Thermo Fisher Scientific, Inc.、Siemens Healthineersなどです。

目次

第1章 調査手法と範囲

• 市場セグメンテーションと範囲
• 地域の範囲
• 推定・予測のタイムライン
• 目的
• 調査手法
• 情報調達
• 情報またはデータ分析
• 市場の形成と検証
• モデル詳細
• 二次情報のリスト
• 略語のリスト

第2章 エグゼクティブサマリー

第3章 血栓止血バイオマーカー市場変数、動向、および範囲

• 血栓止血バイオマーカー市場系統の見通し
  • 親市場の見通し
  • アンシラリーマーケット
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 血栓止血バイオマーカー市場分析ツール
  • ポーターのファイブフォース分析
  • PESTLE分析

第4章 血栓止血バイオマーカー市場- セグメント分析、製品別、2018年から2030年

• 血栓止血バイオマーカー市場：製品の変動分析
• 製品別
  • 分析装置
  • 試薬と消耗品

第5章 血栓止血バイオマーカー市場- セグメント分析、検査場所別、2018年～2030年

• 血栓止血バイオマーカー市場：検査場所の変動分析
• 検査場所別
  • 臨床検査
  • ポイントオブケア検査

第6章 血栓止血バイオマーカー市場- セグメント分析、検査タイプ別、2018年～2030年

• 血栓止血バイオマーカー市場：検査タイプの変動分析
• 検査タイプ別
  • D-ダイマー
  • アンチトロンビンIII
  • プラスミノーゲン
  • フィブリン/フィブリノーゲン
  • 可溶性フィブリン
  • セレクチン
  • 第8因子
  • ポイント
  • アプト
  • その他

第7章 血栓止血バイオマーカー市場- セグメント分析、用途別、2018年から2030年

• 血栓止血バイオマーカー市場：用途の変動分析
• 用途別
  • 深部静脈血栓症（Dvt）
  • 肺塞栓症（Pe）
  • 播種性血管内凝固症候群（Dic）
  • その他

第8章 血栓止血バイオマーカー市場- セグメント分析、最終用途別、2018年～2030年

• 血栓止血バイオマーカー市場：最終用途の変動分析
• 最終用途別
  • 病院とクリニック
  • 学術・調査機関
  • 診断センター
  • その他

第9章 血栓止血バイオマーカー市場：地域別の推定・動向分析、製品別、検査場所、検査タイプ、用途および最終用途別

• 血栓止血市場：地域別の見通し
• 北米
  • 北米の血栓止血バイオマーカー市場推計・予測、2018年から2030年
  • 米国
  • カナダ
• 欧州
  • 欧州の血栓止血バイオマーカー市場推計・予測、2018年から2030年
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • デンマーク
  • スウェーデン
  • ノルウェー
  • その他欧州
• アジア太平洋地域
  • アジア太平洋地域の血栓止血バイオマーカー市場推計・予測、2018年から2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
  • その他アジア太平洋地域
• ラテンアメリカ
  • ラテンアメリカの血栓止血バイオマーカー市場推計・予測、2018年から2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他ラテンアメリカ
• MEA
  • MEA血栓止血バイオマーカー市場推計・予測、2018年から2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート
  • その他中東・アフリカ

第10章 競合情勢

• 企業の分類
• 戦略マッピング
  • 新製品の発売
  • パートナーシップ
  • 取得
  • コラボレーション
  • 資金調達
• 主要企業の市場シェア分析、2022年
• 企業プロファイル
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers
  • Abbott
  • BioMerieux SA
  • Werfen
  • HORIBA Ltd.
  • Quidel Corporation
  • Diazyme Laboratories, Inc.
  • Biomedica Diagnostics

第11章 結論

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 4 Global thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 5 Global thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 6 Global thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 7 Global thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 8 Global thrombosis & hemostasis biomarkers market, by region, 2018 - 2030 (USD Million)
• Table 9 North America thrombosis & hemostasis biomarkers market, by country, 2018 - 2030 (USD Million)
• Table 10 North America thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 11 North America thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 12 North America thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 13 North America thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 14 North America thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 15 U.S. thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 16 U.S. thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 17 U.S. thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 18 U.S. thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 19 U.S. thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 20 Canada thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 21 Canada thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 22 Canada thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 23 Canada thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 24 Canada thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 25 Europe thrombosis & hemostasis biomarkers market, by country, 2018 - 2030 (USD Million)
• Table 26 Europe thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 27 Europe thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 28 Europe thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 29 Europe thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 30 Europe thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 31 Germany thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 32 Germany thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 33 Germany thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 34 Germany thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 35 Germany thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 36 UK thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 37 UK thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 38 UK thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 39 UK thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 40 UK thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 41 France thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 42 France thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 43 France thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 44 France thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 45 France thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 46 Italy thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 47 Italy thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 48 Italy thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 49 Italy thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 50 Italy thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 51 Spain thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 52 Spain thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 53 Spain thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 54 Spain thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 55 Spain thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 56 Denmark thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 57 Denmark thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 58 Denmark thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 59 Denmark thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 60 Denmark thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 61 Sweden thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 62 Sweden thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 63 Sweden thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 64 Sweden thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 65 Sweden thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 66 Norway thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 67 Norway thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 68 Norway thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 69 Norway thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 70 Norway thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 71 Asia Pacific thrombosis & hemostasis biomarkers market, by country, 2018 - 2030 (USD Million)
• Table 72 Asia Pacific thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 73 Asia Pacific thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 74 Asia Pacific thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 75 Asia Pacific thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 76 Asia Pacific thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 77 China thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 78 China thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 79 China thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 80 China thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 81 China thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 82 Japan thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 83 Japan thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 84 Japan thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 85 Japan thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 86 Japan thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 87 India thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 88 India thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 89 India thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 90 India thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 91 India thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 92 South Korea thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 93 South Korea thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 94 South Korea thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 95 South Korea thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 96 South Korea thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 97 Australia thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 98 Australia thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 99 Australia thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 100 Australia thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 101 Australia thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 102 Thailand thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 103 Thailand thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 104 Thailand thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 105 Thailand thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 106 Thailand thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 107 Latin America thrombosis & hemostasis biomarkers market, by country, 2018 - 2030 (USD Million)
• Table 108 Latin America thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 109 Latin America thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 110 Latin America thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 111 Latin America thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 112 Latin America thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 113 Brazil thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 114 Brazil thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 115 Brazil thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 116 Brazil thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 117 Brazil thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 118 Mexico thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 119 Mexico thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 120 Mexico thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 121 Mexico thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 122 Mexico thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 123 Argentina thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 124 Argentina thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 125 Argentina thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 126 Argentina thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 127 Argentina thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 128 Middle East & Africa thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 129 Middle East & Africa thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 130 Middle East & Africa thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 131 Middle East & Africa thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 132 Middle East & Africa thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 133 South Africa thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 134 South Africa thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 135 South Africa thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 136 South Africa thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 137 South Africa thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 138 Saudi Arabia thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 139 Saudi Arabia thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 140 Saudi Arabia thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 141 Saudi Arabia thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 142 Saudi Arabia thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 143 UAE thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 144 UAE thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 145 UAE thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 146 UAE thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 147 UAE thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
• Table 148 Kuwait thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
• Table 149 Kuwait thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
• Table 150 Kuwait thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
• Table 151 Kuwait thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
• Table 152 Kuwait thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Thrombosis & hemostasis biomarkers market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Product and test location segment snapshot
• Fig. 11 Test type segment snapshot
• Fig. 12 Application and end-use segment snapshot
• Fig. 13 Competitive landscape snapshot
• Fig. 14 IVD market value, 2022 (USD Million)
• Fig. 15 Market dynamics
• Fig. 16 Incidence of global pancreatic cancer, 2017 - 2021
• Fig. 17 Porter's five forces analysis
• Fig. 18 PESTLE analysis
• Fig. 19 Thrombosis & hemostasis biomarkers market: Product outlook and key takeaways
• Fig. 20 Thrombosis & hemostasis biomarkers market: Product movement analysis
• Fig. 21 Analyzers Market Estimates and Forecast, 2018 - 2030 (USD Million)
• Fig. 22 Reagents & consumables market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Thrombosis & hemostasis biomarkers market: Test location outlook and key takeaways
• Fig. 24 Thrombosis & hemostasis biomarkers market: Test location movement analysis
• Fig. 25 Clinical laboratory tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Point-of-care tests market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Thrombosis & hemostasis biomarkers market: Test type outlook and key takeaways
• Fig. 28 Thrombosis & hemostasis biomarkers market: Test type movement analysis
• Fig. 29 D- dimer test market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Anti-thrombin III market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Plasminogen market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Fibrin/Fibrinogen Market Estimates and Forecast, 2018-2030, USD Million
• Fig. 33 Soluble fibrin market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Selectins Market Estimates and Forecast, 2018-2030, USD Million
• Fig. 35 Factor VIII market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 PT market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 APTT Market Estimates and Forecast, 2018-2030, USD Million
• Fig. 38 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Thrombosis & hemostasis biomarkers market: Application outlook and key takeaways
• Fig. 40 Thrombosis & hemostasis biomarkers market: Application movement analysis
• Fig. 41 Deep Vein Thrombosis (DVT) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 Pulmonary Embolism (PE) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 Disseminated Intravascular Coagulation (DIC) market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 44 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 45 Thrombosis & hemostasis biomarkers market: End-use outlook and key takeaways
• Fig. 46 Thrombosis & hemostasis biomarkers market: End-use movement analysis
• Fig. 47 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 48 Academic & research institute market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 49 Diagnostic centers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 51 Thrombosis & hemostasis biomarkers market revenue, by region, 2022 & 2030, (USD Million)
• Fig. 52 Regional marketplace: Key takeaways
• Fig. 53 Regional marketplace: Key takeaways
• Fig. 54 North America thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Key country dynamics
• Fig. 56 U.S. thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Key country dynamics
• Fig. 58 Canada thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Europe thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Key country dynamics
• Fig. 61 UK thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Key country dynamics
• Fig. 63 Germany thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Key country dynamics
• Fig. 65 France thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Key country dynamics
• Fig. 67 Spain thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Key country dynamics
• Fig. 69 Italy thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Key country dynamics
• Fig. 71 Denmark thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Key country dynamics
• Fig. 73 Sweden thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Key country dynamics
• Fig. 75 Norway thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Rest of Europe thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD, Million)
• Fig. 77 Asia Pacific thrombosis & hemostasis biomarkers market estimates and forecast, 2018 - 2030, (USD Million)
• Fig. 78 Key country dynamics
• Fig. 79 Japan thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Key country dynamics
• Fig. 81 China thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Key country dynamics
• Fig. 83 India thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Key country dynamics
• Fig. 85 South Korea thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 South Korea reimbursement scenario
• Fig. 87 Key country dynamics
• Fig. 88 Australia thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 89 Key country dynamics
• Fig. 90 Thailand thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 91 Rest of Asia Pacific thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Latin America thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Key country dynamics
• Fig. 94 Brazil thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 95 Key country dynamics
• Fig. 96 Mexico thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 97 Key country dynamics
• Fig. 98 Argentina thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 99 Rest of Latin America thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 100 MEA thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 101 Key country dynamics
• Fig. 102 South Africa thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 103 Key country dynamics
• Fig. 104 Saudi Arabia thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 105 Key country dynamics
• Fig. 106 UAE thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 107 Key country dynamics
• Fig. 108 Kuwait thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 109 Rest of MEA thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 110 Key company categorization
• Fig. 111 Company categorization
• Fig. 112 Company market share analysis, 2022
• Fig. 113 North America - company market share analysis, 2022
• Fig. 114 Europe- company market share analysis, 2022
• Fig. 115 Asia Pacific- company market share analysis, 2022
• Fig. 116 Latin America- company market share analysis, 2022
• Fig. 117 MEA- company market share analysis, 2022
• Fig. 118 Strategic framework

Thrombosis And Hemostasis Biomarkers Market Growth & Trends

The global thrombosis and hemostasis biomarkers market size is expected to reach USD 7.92 Billion by 2030, expanding at a CAGR of 5.90% from 2023 to 2030. The rapid growth of the market is attributable to factors such as the increasing prevalence of chronic diseases such as pancreatic cancer, the rise in the geriatric population, the growing demand for personalized medicines, and advancements in technology.

The thrombosis & hemostasis biomarkers industry has grown significantly in recent years, with changes in adoption patterns and the introduction of novel technologies. The increasing trend of adopting POC analyzers in the market is creating traction for small-sized analyzers. Increasing research on mini- and microdevices is anticipated to continue over the coming years. For instance, in June 2022, Dr. Arnold Lining Ju announced the development of a microdevice that can detect blood clots and can be used to detect early signs of a heart attack.

The prevalence of chronic diseases such as deep vein thrombosis (DVT), pulmonary embolism (PE), and pancreatic cancer is anticipated drive the need for thrombosis & hemostasis biomarkers to detect the probability of hemostasis. Chronic diseases have a tendency to damage blood vessels, leading to the formation of clots that can block blood flow and cause serious health complications, such as stroke & heart attack. For instance, pulmonary embolism (PE), is a serious medical condition that occurs in the legs and travels to the lung, obstructing blood flow.

As per American Lung Association, in January 2023, PE affected nearly 900,000 people in the U.S. and nearly 33% of the people affected by (DVT) or pulmonary embolism (PE) experience recurrence of PE in ten years. Therefore, high prevalence and significant repetition of cases will lead to an increase in the demand for thrombosis & hemostasis biomarkers.

Furthermore, key players operating in the market are focusing on different forms of strategic initiatives such as mergers and acquisitions to increase their respective position in the thrombosis & hemostasis biomarkers industry. For instance, in January 2023, Thermo Fisher Scientific, Inc., announced a partnership with AstraZeneca to manufacture a blood-based and solid tissue companion diagnostic test for Tagrisso. This was expected to propel the thrombosis and hemostasis biomarkers industry. Additionally, in May 2022, Quidel Corporation acquired Ortho Clinical Diagnostics for USD 6 billion. The new company was named QuidelOrtho. Through this acquisition, Quidel gained access to Ortho Clinical Diagnostics' biomarker tests portfolio.

Thrombosis And Hemostasis Biomarkers Market Report Highlights

• Reagents and consumables segment of the market held the largest revenue share in 2022 and is attributable to the heightened prevalence of bleeding and coagulation disorders in the global population
• Clinical laboratory tests led the overall market in 2022, owing to their ability to diagnose and identify abnormalities in the blood clotting process while processing a high volume of samples
• Post-thrombin (PT) test held the largest revenue share in 2022, attributable to the test quality which allows monitoring the effectiveness of anticoagulant medications
• Deep Vein Thrombosis (DVT) held the largest revenue share in 2022, owing to its high prevalence and the high mortality risk
• Diagnostic centers held the largest revenue share in 2022, attributable to the growing reliance of hospitals on diagnostic centers for testing and the presence of specialized equipment to provide faster test results
• North America dominated the market in 2022 which can be attributed to a significant prevalence of thrombosis and hemostasis disorders, along with access to advanced technology
• A few of the key market playersinclude bioMerieux SA; Abbott; Werfen; HORIBA Ltd.; Quidel Corporation; F. Hoffmann-La Roche Ltd.; Diazyme Laboratories, Inc.; Biomedica Diagnostics; Thermo Fisher Scientific, Inc.; Siemens Healthineers.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment Definitions
    • 1.1.1.1 Product Segment
    • 1.1.1.2 Test Location Segment
    • 1.1.1.3 Test Type Segment
    • 1.1.1.4 Application Segment
    • 1.1.1.5 End-Use Segment
• 1.2 Regional Scope
• 1.3 Estimates And Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 Gvr's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Product And Test Location Segment Snapshot
• 2.3 Test Type Segment Snapshot
• 2.4 Application And End Use Segment Snapshot
• 2.5 Competitive Landscape Snapshot

Chapter 3 Thrombosis & Hemostasis Biomarkers Market Variables, Trends, And Scope

• 3.1 Thrombosis & Hemostasis Biomarkers Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
  • 3.1.2 Ancillary Market
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Analysis
    • 3.2.1.1 Increasing Prevalence Of Chronic Diseases
    • 3.2.1.1.1 Incidence Data Of Pancreatic Cancer
    • 3.2.1.2 Growing Geriatric Population
    • 3.2.1.3 Increasing Demand For Personalized Medicine
    • 3.2.1.4 Advancements In Technology
  • 3.2.2 Market Restraint Analysis
    • 3.2.2.1 High Cost Of Diagnostic Tests
    • 3.2.2.2 Complexity Of Thrombotic Events
• 3.3 Thrombosis & Hemostasis Biomarkers Market Analysis Tools
  • 3.3.1 Porter's Five Forces Analysis
  • 3.3.2 Pestle Analysis

Chapter 4 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Product, 2018 - 2030 (USD Million)

• 4.1 Thrombosis & Hemostasis Biomarkers Market: Product Movement Analysis
• 4.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Product (USD Million)
  • 4.2.1 Analyzers
  • 4.2.2 Reagents & Consumables

Chapter 5 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Test Location, 2018 - 2030 (USD Million)

• 5.1 Thrombosis & Hemostasis Biomarkers Market: Test Location Movement Analysis
• 5.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Test Location (USD Million)
  • 5.2.1 Clinical Laboratory Tests
  • 5.2.2 Point-Of-Care Tests

Chapter 6 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Test Type, 2018 - 2030 (USD Million)

• 6.1 Thrombosis & Hemostasis Biomarkers Market: Test Type Movement Analysis
• 6.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Test Type (USD Million)
  • 6.2.1 D-Dimer
  • 6.2.2 Anti-Thrombin Iii
  • 6.2.3 Plasminogen
  • 6.2.4 Fibrin/Fibrinogen
  • 6.2.5 Soluble Fibrin
  • 6.2.6 Selectins
  • 6.2.7 Factor Viii
  • 6.2.8 Pt
  • 6.2.9 Aptt
  • 6.2.10 Others

Chapter 7 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Application, 2018 - 2030 (USD Million)

• 7.1 Thrombosis & Hemostasis Biomarkers Market: Application Movement Analysis
• 7.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Application (USD Million)
  • 7.2.1 Deep Vein Thrombosis (Dvt)
  • 7.2.2 Pulmonary Embolism (Pe)
  • 7.2.3 Disseminated Intravascular Coagulation (Dic)
  • 7.2.4 Others

Chapter 8 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By End Use, 2018 - 2030 (USD Million)

• 8.1 Thrombosis & Hemostasis Biomarkers Market: End-Use Movement Analysis
• 8.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By End Use (USD Million)
  • 8.2.1 Hospitals & Clinics
  • 8.2.2 Academic & Research Institute
  • 8.2.3 Diagnostic Centers
  • 8.2.4 Others

Chapter 9 Thrombosis & Hemostasis Biomarkers Market: Regional Estimates And Trend Analysis, By Product, Test Location, Test Type, Application, & End-Use

• 9.1 Thrombosis & Hemostasis Market: Regional Outlook
• 9.2 North America
  • 9.2.1 North America Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.2.2 U.S.
    • 9.2.2.1 Key Country Dynamics
    • 9.2.2.2 Target Disease Prevalence
    • 9.2.2.3 U.S. Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2.4 Competitive Scenario
    • 9.2.2.5 Regulatory Framework
    • 9.2.2.6 Reimbursement Scenario
  • 9.2.3 Canada
    • 9.2.3.1 Key Country Dynamics
    • 9.2.3.2 Target Disease Prevalence
    • 9.2.3.3 Canada Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.2.3.4 Competitive Scenario
    • 9.2.3.5 Regulatory Framework
    • 9.2.3.6 Reimbursement Scenario
• 9.3 Europe
  • 9.3.1 Europe Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.3.2 Uk
    • 9.3.2.1 Key Country Dynamics
    • 9.3.2.2 Target Disease Prevalence
    • 9.3.2.3 Uk Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2.4 Competitive Scenario
    • 9.3.2.5 Regulatory Framework
    • 9.3.2.6 Reimbursement Scenario
  • 9.3.3 Germany
    • 9.3.3.1 Key Country Dynamics
    • 9.3.3.2 Target Disease Prevalence
    • 9.3.3.3 Germany Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.3.4 Competitive Scenario
    • 9.3.3.5 Regulatory Framework
    • 9.3.3.6 Reimbursement Scenario
  • 9.3.4 France
    • 9.3.4.1 Key Country Dynamics
    • 9.3.4.2 Target Disease Prevalence
    • 9.3.4.3 France Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.4.4 Competitive Scenario
    • 9.3.4.5 Regulatory Framework
    • 9.3.4.6 Reimbursement Scenario
  • 9.3.5 Spain
    • 9.3.5.1 Key Country Dynamics
    • 9.3.5.2 Target Disease Prevalence
    • 9.3.5.3 Spain Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.5.4 Competitive Scenario
    • 9.3.5.5 Regulatory Framework
    • 9.3.5.6 Reimbursement Scenario
  • 9.3.6 Italy
    • 9.3.6.1 Key Country Dynamics
    • 9.3.6.2 Target Disease Prevalence
    • 9.3.6.3 Italy Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.6.4 Competitive Scenario
    • 9.3.6.5 Regulatory Framework
    • 9.3.6.6 Reimbursement Scenario
  • 9.3.7 Denmark
    • 9.3.7.1 Key Country Dynamics
    • 9.3.7.2 Target Disease Prevalence
    • 9.3.7.3 Denmark Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.7.4 Competitive Scenario
    • 9.3.7.5 Regulatory Framework
    • 9.3.7.6 Reimbursement Scenario
  • 9.3.8 Sweden
    • 9.3.8.1 Key Country Dynamics
    • 9.3.8.2 Target Disease Prevalence
    • 9.3.8.3 Sweden Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.8.4 Competitive Scenario
    • 9.3.8.5 Regulatory Framework
    • 9.3.8.6 Reimbursement Scenario
  • 9.3.9 Norway
    • 9.3.9.1 Key Country Dynamics
    • 9.3.9.2 Target Disease Prevalence
    • 9.3.9.3 Norway Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.9.4 Competitive Scenario
    • 9.3.9.5 Regulatory Framework
    • 9.3.9.6 Reimbursement Scenario
  • 9.3.10 Rest Of Europe
• 9.4 Asia Pacific
  • 9.4.1 Asia Pacific Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.4.2 Japan
    • 9.4.2.1 Key Country Dynamics
    • 9.4.2.2 Death Rate In Japan
    • 9.4.2.3 Target Disease Prevalence
    • 9.4.2.4 Japan Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2.5 Competitive Scenario
    • 9.4.2.6 Regulatory Framework
    • 9.4.2.7 Reimbursement Scenario
  • 9.4.3 China
    • 9.4.3.1 Key Country Dynamics
    • 9.4.3.2 Target Disease Prevalence
    • 9.4.3.3 China Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.3.4 Competitive Scenario
    • 9.4.3.5 Regulatory Framework
    • 9.4.3.6 Reimbursement Scenario
  • 9.4.4 India
    • 9.4.4.1 Key Country Dynamics
    • 9.4.4.2 Target Disease Prevalence
    • 9.4.4.3 India Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.4.4 Competitive Scenario'
    • 9.4.4.5 Regulatory Framework
    • 9.4.4.6 Reimbursement Scenario
  • 9.4.5 South Korea
    • 9.4.5.1 Key Country Dynamics
    • 9.4.5.2 Target Disease Prevalence
    • 9.4.5.3 South Korea Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.5.4 Competitive Scenario
    • 9.4.5.5 Regulatory Framework
    • 9.4.5.6 Reimbursement Scenario
  • 9.4.6 Australia
    • 9.4.6.1 Key Country Dynamics
    • 9.4.6.2 Target Disease Prevalence
    • 9.4.6.3 Australia Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.6.4 Competitive Scenario
    • 9.4.6.5 Regulatory Framework
    • 9.4.6.6 Reimbursement Scenario
  • 9.4.7 Thailand
    • 9.4.7.1 Key Country Dynamics
    • 9.4.7.2 Target Disease Prevalence
    • 9.4.7.3 Thailand Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.7.4 Competitive Scenario
    • 9.4.7.5 Regulatory Framework
    • 9.4.7.6 Reimbursement Scenario
  • 9.4.8 Rest Of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Latin America Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5.2 Brazil
    • 9.5.2.1 Key Country Dynamics
    • 9.5.2.2 Brazil Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2.3 Target Disease Prevalence
    • 9.5.2.4 Competitive Scenario
    • 9.5.2.5 Regulatory Framework
    • 9.5.2.6 Reimbursement Scenario
  • 9.5.3 Mexico
    • 9.5.3.1 Key Country Dynamics
    • 9.5.3.2 Target Disease Prevalence
    • 9.5.3.3 Mexico Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.3.4 Competitive Scenario
    • 9.5.3.5 Regulatory Framework
    • 9.5.3.6 Reimbursement Scenario
  • 9.5.4 Argentina
    • 9.5.4.1 Key Country Dynamics
    • 9.5.4.2 Target Disease Prevalence
    • 9.5.4.3 Argentina Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.4.4 Competitive Scenario
    • 9.5.4.5 Regulatory Framework
    • 9.5.4.6 Reimbursement Scenario
  • 9.5.5 Rest Of Latin America
• 9.6 MEA
  • 9.6.1 MEA Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.6.2 South Africa
    • 9.6.2.1 Key Country Dynamics
    • 9.6.2.2 Target Disease Prevalence
    • 9.6.2.3 South Africa Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2.4 Competitive Scenario
    • 9.6.2.5 Regulatory Framework
    • 9.6.2.6 Reimbursement Scenario
  • 9.6.3 Saudi Arabia
    • 9.6.3.1 Key Country Dynamics
    • 9.6.3.2 Target Disease Prevalence
    • 9.6.3.3 Saudi Arabia Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.6.3.4 Competitive Scenario
    • 9.6.3.5 Regulatory Framework
    • 9.6.3.6 Reimbursement Scenario
  • 9.6.4 UAE
    • 9.6.4.1 Key Country Dynamics
    • 9.6.4.2 Target Disease Prevalence
    • 9.6.4.3 Uae Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.6.4.4 Competitive Scenario
    • 9.6.4.5 Regulatory Framework
    • 9.6.4.6 Reimbursement Scenario
  • 9.6.5 Kuwait
    • 9.6.5.1 Key Country Dynamics
    • 9.6.5.2 Target Disease Prevalence
    • 9.6.5.3 Kuwait Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.6.5.4 Competitive Scenario
    • 9.6.5.5 Regulatory Framework
    • 9.6.5.6 Reimbursement Scenario
  • 9.6.6 Rest Of Mea

Chapter 10 Competitive Landscape

• 10.1 Company Categorization
• 10.2 Strategy Mapping
  • 10.2.1 New Product Launch
  • 10.2.2 Partnerships
  • 10.2.3 Acquisition
  • 10.2.4 Collaboration
  • 10.2.5 Funding
• 10.3 Key Company Market Share Analysis, 2022
• 10.4 Company Profiles
  • 10.4.1 Thermo Fisher Scientific, Inc.
    • 10.4.1.1 Company Overview
    • 10.4.1.2 Financial Performance
    • 10.4.1.3 Product Benchmarking
    • 10.4.1.4 Strategic Initiatives
  • 10.4.2 F. Hoffmann-La Roche Ltd.
    • 10.4.2.1 Company Overview
    • 10.4.2.2 Financial Performance
    • 10.4.2.3 Product Benchmarking
    • 10.4.2.4 Strategic Initiatives
  • 10.4.3 Siemens Healthineers
    • 10.4.3.1 Company Overview
    • 10.4.3.2 Financial Performance
    • 10.4.3.3 Product Benchmarking
    • 10.4.3.4 Strategic Initiatives
  • 10.4.4 Abbott
    • 10.4.4.1 Company Overview
    • 10.4.4.2 Financial Performance
    • 10.4.4.3 Product Benchmarking
    • 10.4.4.4 Strategic Initiatives
  • 10.4.5 BioMerieux SA
    • 10.4.5.1 Company Overview
    • 10.4.5.2 Financial Performance
    • 10.4.5.3 Product Benchmarking
    • 10.4.5.4 Strategic Initiative
  • 10.4.6 Werfen
    • 10.4.6.1 Company Overview
    • 10.4.6.2 Financial Performance
    • 10.4.6.3 Product Benchmarking
    • 10.4.6.4 Strategic Initiatives
  • 10.4.7 HORIBA Ltd.
    • 10.4.7.1 Company Overview
    • 10.4.7.2 Financial Performance
    • 10.4.7.3 Product Benchmarking
    • 10.4.7.4 Strategic Initiatives
  • 10.4.8 Quidel Corporation
    • 10.4.8.1 Company Overview
    • 10.4.8.2 Financial Performance
    • 10.4.8.3 Product Benchmarking
    • 10.4.8.4 Strategic Initiatives
  • 10.4.9 Diazyme Laboratories, Inc.
    • 10.4.9.1 Company Overview
    • 10.4.9.2 Financial Performance
    • 10.4.9.3 Product Benchmarking
    • 10.4.9.4 Strategic Initiatives
  • 10.4.10 Biomedica Diagnostics
    • 10.4.10.1 Company Overview
    • 10.4.10.2 Financial Performance
    • 10.4.10.3 Product Benchmarking
    • 10.4.10.4 Strategic Initiatives

Chapter 11 Conclusion